Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Rizvi, N. A.; Brahmer, J. R.; Ou, S. H. I.; Segal, N. H.; Khleif, S.; Hwu, W. J.; Gutierrez, M.; Schöffski, P.; Hamid, O.; Weiss, J.; Lutzky, J.; Maio, M.; Nemunaitis, J. J.; Jaeger, D.; Balmanoukian, A. S.; Rebelatto, M.; Steele, K.; Li, X.; Blake-Haskins, J. A.; Antonia, S. J. |
| Abstract Title: | Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901745 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2015.33.15_suppl.8032 |
| Notes: | Meeting Abstract: 8032 -- Source: Wos |
